Ghrelin and cachexia in chronic kidney disease

Pediatric Nephrology

Volumn 28, Issue 4, 2013, Pages 521-526

  Suzuki, Hajime ^a   Asakawa, Akihiro ^a   Amitani, Haruka ^a   Nakamura, Norifumi ^a   Inui, Akio ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Cachexia; Chronic kidney disease; Cytokine; Feeding regulatory peptide; Ghrelin

Indexed keywords

ALPHA INTERMEDIN; CASPASE 3; GHRELIN; GHRELIN RECEPTOR; INTERMEDIN; MELANOCORTIN; MELANOCORTIN 4 RECEPTOR; PROOPIOMELANOCORTIN; ROSIGLITAZONE; ANTIINFLAMMATORY AGENT; APPETITE STIMULANT; AUTACOID; CYTOKINE;

ANTIINFLAMMATORY ACTIVITY; ARCUATE NUCLEUS; CACHEXIA; CHILDHOOD DISEASE; CHRONIC KIDNEY DISEASE; DECREASED APPETITE; DIABETES MELLITUS; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; FEEDING BEHAVIOR; FOOD INTAKE; GASTROINTESTINAL MOTILITY; HEMODIALYSIS PATIENT; HUMAN; HYPOALBUMINEMIA; HYPOTHALAMUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; MALNUTRITION; MORBIDITY; MORTALITY; NERVE CELL; NERVE ENDING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; RENAL REPLACEMENT THERAPY; REVIEW; SKELETAL MUSCLE; WASTING SYNDROME; WEIGHT REDUCTION; ANIMAL; CHRONIC KIDNEY FAILURE; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGICAL ASPECT; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; APPETITE REGULATION; APPETITE STIMULANTS; CACHEXIA; CYTOKINES; GHRELIN; HUMANS; HYPOTHALAMUS; INFLAMMATION MEDIATORS; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

MLCS; MLOWN;

EID: 84879963081     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-012-2241-6     Document Type: Review

References (50)

1. Deboer MD, Marks DL (2006) Therapy insight: Use of melanocortin antagonists in the treatment of cachexia in chronic disease. Nat Clin Pract Endocrinol Metab 2:459-466
2. Mak RH, Cheung W (2006) Energy homeostasis and cachexia in chronic kidney disease. Pediatr Nephrol 21:1807-1814
3. Deboer MD, Zhu X, Levasseur PR, Inui A, Hu Z, Han G, Mitch WE, Taylor JE, Halem HA, Dong JZ, Datta R, Culler MD, Marks DL (2008) Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology 149:827-835
4. Deboer MD (2007) Melanocortin interventions in cachexia: how soon from bench to bedside? Curr Opin Clin Nutr Metab Care 10:457-462
5. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S (2001) A role for ghrelin in the central regulation of feeding. Nature 409:194-198
6. Sun Y (2004) Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci USA 101:4679-4684
7. Mak RH, Ikizler AT, Kovesdy CP, Raj DS, Stenvinkel P, Kalantar-Zadeh K (2011) Wasting in chronic kidney disease. J Cachex Sarcopenia Muscle 2:9-25
8. Nass RM, Gaylinn BD, Rogol AD, Thorner MO (2010) Ghrelin and growth hormone: story in reverse. Proc Natl Acad Sci USA 107:8501-8502
9. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656-660
10. Kirchner H, Gutierrez JA, Solenberg PJ, Pfluger PT, Czyzyk TA, Willency JA, Schürmann A, Joost HG, Jandacek RJ, Hale JE, Heiman ML, Tschöp MH (2009) GOAT links dietary lipids with the endocrine control of energy balance. Nat Med 15:741-745
11. Akamizu T, Takaya K, Irako T, Hosoda H, Teramukai S, Matsuyama A, Tada H, Miura K, Shimizu A, Fukushima M, Yokode M, Tanaka K, Kangawa K (2004) Pharmacokinetics, safety, and endocrine and appetite effects of ghrelin administration in young healthy subjects. Eur J Endocrinol 150:447-455
12. Hosoda H, Kojima M, Matsuo H, Kangawa K (2000) Ghrelin and des-acyl ghrelin: two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res Commun 279:909-913
13. Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga M (2005) Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 54:18-24
14. Chen CY, Inui A, Asakawa A, Fujino K, Kato I, Chen CC, Ueno N, Fujimiya M (2005) Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology 129:8-25
15. Inui A (2001) Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2:551-560
16. Guan XM, Yu H, Palyha OC, McKee KK, Feighner SD, Sirinathsinghji DJ, Smith RG, Van der Ploeg LH, Howard AD (1997) Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissues. Brain Res Mol Brain Res 48:23-29
17. Laviano A, Inui A, Marks DL, Meguid MM, Pichard C, Rossi Fanelli F, Seelaender M (2008) Neural control of the anorexia-cachexia syndrome. Am J Physiol Endocrinol Metab 295:E1000-E1008
18. Wardlaw SL (2011) Hypothalamic proopiomelanocortin processing and the regulation of energy balance. Eur J Pharmacol 660:213-219
19. Cone RD (2005) Anatomy and regulation of the central melanocortin system. Nat Neurosci 8:571-578
20. Büscher AK, Büscher R, Hauffa BP, Hoyer PF (2010) Alterations in appetite-regulating hormones influence protein-energy wasting in pediatric patients with chronic kidney disease. Pediatr Nephrol 25:2295-2301
21. Bergström J (1995) Why are dialysis patients malnourished? Am J Kidney Dis 26:229-241
22. Mitch WE (1998) Robert H Herman Memorial Award in Clinical Nutrition Lecture, 1997. Mechanisms causing loss of lean body mass in kidney disease. Am J Clin Nutr 67:359-366
23. Heimbürger O, Lönnqvist F, Danielsson A, Nordenström J, Stenvinkel P (1997) Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J Am Soc Nephrol 8:1423-1430
24. Shinohara K, Shoji T, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y (2002) Insulin resistance as an independent predictor of cardiovascular mortality in patients with end-stage renal disease. J Am Soc Nephrol 13:1894-1900
25. Siew ED, Pupim LB, Majchrzak KM, Shintani A, Flakoll PJ, Ikizler TA (2007) Insulin resistance is associated with skeletal muscle protein breakdown in non-diabetic chronic hemodialysis patients. Kidney Int 71:146-152
26. Bailey JL, Zheng B, Hu Z, Price SR, Mitch WE (2006) Chronic kidney disease causes defects in signaling through the insulin receptor substrate/ phosphatidylinositol 3-kinase/ Akt pathway: implications for muscle atrophy. J Am Soc Nephrol 17:1388-1394
27. Mitch WE, Goldberg AL (1996) Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 335:1897-1905
28. Mitch WE (2002) Malnutrition: a frequent misdiagnosis for hemodialysis patients. J Clin Invest 110:437-439
29. Goodman MN (1991) Tumor necrosis factor induces skeletal muscle protein breakdown in rats. Am J Physiol 260:E727-E730
30. Du J, Wang X, Miereles C, Bailey JL, Debigare R, Zheng B, Price SR, Mitch WE (2004) Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 113:115-123
31. Lee SW, Dai G, Hu Z, Wang X, Du J, Mitch WE (2004) Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol 15:1537-1545
32. Cheung W, Yu PX, Little BM, Cone RD, Marks DL, Mak RH (2005) Role of leptin and melanocortin signaling in uremia-associated cachexia. J Clin Invest 115:1659-1665
33. Barazzoni R, Bosutti A, Stebel M, Cattin MR, Roder E, Visintin L, Cattin L, Biolo G, Zanetti M, Guarnieri G (2005) Ghrelin regulates mitochondrial-lipid metabolism gene expression and tissue fat distribution in liver and skeletal muscle. Am J Physiol Endocrinol Metab 288:E228-E235
34. Barazzoni R, Zanetti M, Cattin MR, Visintin L, Vinci P, Cattin L, Stebel M, Guarnieri G (2007) Ghrelin enhances in vivo skeletal muscle but not liver AKT signaling in rats. Obesity (Silver Spring) 15:2614-2623
35. Barazzoni R, Zhu X, Deboer M, Datta R, Culler MD, Zanetti M, Guarnieri G, Marks DL (2010) Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease. Kidney Int 77:23-28
36. Barazzoni R, Zanetti M, Ferreira C, Vinci P, Pirulli A, Mucci M, Dore F, Fonda M, Ciocchi B, Cattin L, Guarnieri G (2007) Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab 92:3935-3940
37. Barazzoni R, Zanetti M, Stulle M, Mucci MP, Pirulli A, Dore F, Panzetta G, Vasile A, Biolo G, Guarnieri G (2008) Higher total ghrelin levels are associated with higher insulin-mediated glucose disposal in non-diabetic maintenance hemodialysis patients. Clin Nutr 27:142-149
38. Carrero JJ, Nakashima A, Qureshi AR, Lindholm B, Heimburger O, Barany P, Stenvinkel P (2011) Protein-energy wasting modifies the association of ghrelin with inflammation, leptin, and mortality in hemodialysis patients. Kidney Int 79:749-756
39. Yoshimoto A, Mori K, Sugawara A, Mukoyama M, Yahata K, Suganami T, Takaya K, Hosoda H, Kojima M, Kangawa K, Nakao K (2002) Plasma ghrelin and desacyl ghrelin concentrations in renal failure. J Am Soc Nephrol 13:2748-2752
40. Naufel MF, Bordon M, de Aquino TM, Ribeiro EB, de Abreu Carvalhaes JT (2010) Plasma levels of acylated and total ghrelin in pediatric patients with chronic kidney disease. Pediatr Nephrol 25:2477-2482
41. Arbeiter AK, Büscher R, Petersenn S, Hauffa BP, Mann K, Hoyer PF (2008) Ghrelin and other appetite-regulating hormones in paediatric patients with chronic renal failure during dialysis and following kidney transplantation. Nephrol Dial Transplant 24:643-646
42. Iglesias P, Díez JJ, Fernández-Reyes MJ, Codoceo R, Alvarez-Fidalgo P, Bajo MA, Aguilera A, Selgas R (2005) Serum ghrelin concentrations in patients with chronic renal failure undergoing dialysis. Clin Endocrinol (Oxf) 64:68-73
43. Jarkovská Z, Hodková M, Sazamová M, Rosická M, Dusilová-Sulková S, Marek J, Justová V, Lacinová Z, Haluzík M, Haas T, Krsek M (2005) Plasma levels of active and total ghrelin in renal failure: a relationship with GH/IGF-I axis. Growth Horm IGF Res 15:369-376
44. Rodriguez Ayala E, Pecoits-Filho R, Heimbürger O, Lindholm B, Nordfors L, Stenvinkel P (2004) Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study. Nephrol Dial Transplant 19:421-426
45. Pérez-Fontán M, Cordido F, Rodríguez-Carmona A, García-Naveiro R, Isidro ML, Villaverde P, García-Buela J (2005) Acute plasma ghrelin and leptin responses to oral feeding or intraperitoneal hypertonic glucose-based dialysate in patients with chronic renal failure. Kidney Int 68:2877-2885
46. Mak RH, Cheung WW (2011) Is ghrelin a biomarker for mortality in end-stage renal disease? Kidney Int 79:697-699
47. DeBoer MD (2008) Emergence of ghrelin as a treatment for cachexia syndromes. Nutrition 24:806-814
48. Ashby DR, Ford HE, Wynne KJ, Wren AM, Murphy KG, Busbridge M, Brown EA, Taube DH, Ghatei MA, Tam FW, Bloom SR, Choi P (2009) Sustained appetite improvement in malnourished dialysis patients by daily ghrelin treatment. Kidney Int 76:199-206
49. Venables G, Hunne B, Bron R, Cho HJ, Brock JA, Furness JB (2011) Ghrelin receptors are expressed by distal tubules of the mouse kidney. Cell Tissue Res 346:135-139
50. Kemp BA, Howell NL, Gray JT, Keller SR, Nass RM, Padia SH (2011) Intrarenal ghrelin infusion stimulates distal nephron-dependent sodium reabsorption in normal rats. Hypertension 57:633-639